Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Etrasimod Arginine
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
European Commission Approves Pfizer’s VELSIPITY® for Ulcerative Colitis
Details : Velsipity (etrasimod) is an oral S1P receptor modulator approved for treating moderately to severely active ulcerative colitis.
Brand Name : Velsipity
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 19, 2024
Lead Product(s) : Etrasimod Arginine
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?